Design Therapeautics, Inc. share price logo

Design Therapeautics, Inc. Share Price

NASDAQ: DSGN

Small Cap

$6.50

+0.01

(+0.15%)

Live

as on

Design Therapeautics, Inc. Stock Performance

as on October 30, 2025 at 7:34 pm IST

  • Day's Low

    $6.44
    $6.5
    downward going graph

    0.92%

    Downside

  • 52 Week's Low

    52 Week's High

    $2.6
    $7.77
    downward going graph

    60.00%

    Downside

    19.54%

    Upside

    downward going graph

Design Therapeautics, Inc. share price movements today

Previous Close
$6.49
Open
$6.44
Volume
7.2K
Day's Low - High
$6.44 - $6.5
52 Week Low - High
$2.6 - $7.77

Design Therapeautics, Inc. Historical Returns

1 Month Return
-13.81 %
3 Month Return
+ 61.04 %
1 Year Return
+ 16.52 %
3 Year Return
-59.69 %
5 Year Return
0 %

Design Therapeautics, Inc. Stock Fundamentals & Key Indicators

Check Design Therapeautics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$380.4M

EPS (TTM)

-1.3367

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-74.3M

Revenue (TTM)

33.0K

Profit Margin

0.00%

Return On Equity TTM

-26.77%

Design Therapeautics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Design Therapeautics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Design Therapeautics, Inc. image
Design Therapeautics, Inc.
HOLD$380.4MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$62.4B291.63%-505.15-12.96%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$36.4BNANA-3.89%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$108.3B100.24%30.0231.86%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$69.4B20.12%15.732.13%

Stock Returns calculator for Design Therapeautics, Inc. Stock including INR - Dollar returns

The Design Therapeautics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Design Therapeautics, Inc. investment value today

Current value as on today

₹1,22,363

Returns

₹22,363

(+22.36%)

Returns from Design Therapeautics, Inc. Stock

₹16,697 (+16.7%)

Dollar Returns*

₹5,667 (+5.67%)

Analyst Recommendation on Design Therapeautics, Inc. Stock

Based on 8 analysts

HOLD

0.00%

Buy

62.50%

Hold

37.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'HOLD' rating for Design Therapeautics, Inc.. Average target price of $7.33

Design Therapeautics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Design Therapeautics, Inc..

What analysts predicted

11.32%UPSIDE

Target Price

$7.33

Current Price

$6.5

Analyzed by

8 Analysts

Target

$7.33

Design Therapeautics, Inc. target price $7.33, a slight upside of 11.32% compared to current price of $6.5. According to 8 analysts rating.

Design Therapeautics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
0
-
-
-
0
-
-
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-21
-22
-18
-15
-14
-15
-16
-16
-20
-21
EBITDA
-21
-22
-18
-14
-14
-14
-16
-16
-20
-21
Interest Expense
0
-
-
0
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-19
-19
-15
-11
-11
-11
-13
-13
-17
-19
Income Tax Expense
-2
0
0
2
0
-
-
-
-
-
Net Income
-16
-19
-15
-11
-11
-11
-13
-13
-17
-19
Net Profit Margin
0.00%
0.00%
0.00%
-1413.13%
0.00%
0.00%
0.00%
-2321.60%
0.00%
0.00%

Design Therapeautics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
0
0
-
-
-
-
Gross Profit
0
0
0
0
0
0
Operating Income
-1
-8
-35
-67
-78
-62
EBITDA
-1
-8
-35
-67
-66
-48
Interest Expense
-
-
0
4
-
-
Depreciation
-
0
0
0
0
0
Income Before Tax
-2
-8
-35
-63
-66
-49
Income Tax Expense
0
0
0
-4
0
-
Net Income
-2
-8
-35
-58
-66
-49
Net Profit Margin
-245.44%
-3663716.81%
0.00%
0.00%
0.00%
0.00%

Design Therapeautics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-19
-15
-11
-11
-11
-13
-13
-17
-19
Operating Cash Flow
-13
-14
-12
-12
-11
-9
-9
-16
-14
Investing Cash Flow
11
15
5
20
27
-5
1
7
20
Financing Cash Flow
0
0
0
0
0
0
0
0
0
Change in Cash
-1
0
-6
8
16
-15
-7
-8
6

Design Therapeautics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-8
-35
-63
-66
-49
Operating Cash Flow
-8
-29
-51
-58
-43
Investing Cash Flow
-33
-53
-220
52
43
Financing Cash Flow
44
379
0
0
0
Change in Cash
2
296
-272
-5
1

Global Institutional Holdings in Design Therapeautics, Inc.

Funds
Holdings
SR ONE CAPITAL MANAGEMENT, LP
11.46%
Logos Global Management LP
7.41%
BlackRock Inc
4.21%
Point72 Asset Management, L.P.
3.17%
TANG CAPITAL MANAGEMENT LLC
3.13%
See all

Insights on Design Therapeautics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, DSGN stock has moved up by 13.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 71.1% return, outperforming this stock by 54.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 135.5% return, outperforming this stock by 195.2%

About Design Therapeautics, Inc.

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
OrganisationDesign Therapeautics, Inc.
Headquarters6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
IndustryHealthcare
CEOMr. Pratik Shah Ph.D.
E-voting on sharesClick here to vote

Key Management of Design Therapeautics, Inc.

Name

Title

Mr. Pratik Shah Ph.D.

Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson

Dr. Sean Jeffries Ph.D.

Chief Operating Officer

Dr. Aseem Z. Ansari Ph.D.

Co-Founder & Scientific Advisor

Dr. Chris M. Storgard M.D.

Chief Medical Officer

Mr. Jim Kerr

Chief of Manufacturing & Product Development

Dr. Chengzhi Zhang Ph.D.

Chief Chemist

Ms. Julie D. Burgess CPA

Chief Accounting Officer

Mr. Doane Chilcoat Ph.D.

Chief Technology Officer

Mr. Mustapha Parekh

General Counsel

Dr. Tadimeti S. Rao Ph.D.

Chief Scientific Officer

FAQs

What is Design Therapeautics, Inc. share price today?

Design Therapeautics, Inc. share price today is $6.5 as on . Design Therapeautics, Inc. share today touched a day high of $6.5 and a low of $6.44.

What is the 52 week high and 52 week low for Design Therapeautics, Inc. share?

Design Therapeautics, Inc. share touched a 52 week high of $7.77 on and a 52 week low of $2.6 on . Design Therapeautics, Inc. stock price today i.e. is trending at $6.5,which is 16.34% down from its 52 week high and 150.00% up from its 52 week low.

What is Design Therapeautics, Inc.'s market capitalisation today?

Design Therapeautics, Inc. market capitalisation is $0.00T as on .

How to invest in Design Therapeautics, Inc. Stock (DSGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Design Therapeautics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Design Therapeautics, Inc. Shares that will get you 0.2308 shares as per Design Therapeautics, Inc. share price of $6.5 per share as on October 30, 2025 at 7:34 pm IST.

What is the minimum amount required to buy Design Therapeautics, Inc. Stock (DSGN) from India?

Indian investors can start investing in Design Therapeautics, Inc. (DSGN) shares with as little as ₹88.686 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹886.86 in Design Therapeautics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Design Therapeautics, Inc. share’s latest price of $6.5 as on October 30, 2025 at 7:34 pm IST, you will get 1.5385 shares of Design Therapeautics, Inc.. Learn more about fractional shares .